GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

Longtime drug developer Suma Krishnan was 51 when she cofounded Krystal Biotech. Now the company has one gene therapy on the ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

According to the latest study from BCC Research, "Biologic Therapeutic Drugs: Technologies and Global Markets" is projected ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

Top Pharmaceuticals and Healthcare Stocks in India - Check out the top-performing Pharmaceuticals and Healthcare stocks in India with our sectoral stock screener. Analyze market cap, P/E ratio, return ...

This article highlights the top B.Tech Biotechnology colleges in India for 2025, detailing their course durations, fees, and ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state. The company said Monday ...